AC Immune (NASDAQ:ACIU) Shares Up 7.1%

Shares of AC Immune SA (NASDAQ:ACIU) shot up 7.1% on Monday . The stock traded as high as $5.44 and last traded at $5.41, 482,880 shares were traded during mid-day trading. An increase of 53% from the average session volume of 316,305 shares. The stock had previously closed at $5.05.

Several brokerages recently weighed in on ACIU. HC Wainwright set a $8.00 price target on AC Immune and gave the stock a “buy” rating in a research note on Friday, July 12th. BidaskClub downgraded AC Immune from a “buy” rating to a “hold” rating in a report on Wednesday, August 28th. Finally, ValuEngine raised AC Immune from a “sell” rating to a “hold” rating in a report on Wednesday, June 12th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. AC Immune has an average rating of “Hold” and a consensus target price of $11.94.

The company has a quick ratio of 21.90, a current ratio of 21.90 and a debt-to-equity ratio of 0.01. The company has a fifty day simple moving average of $5.34 and a 200 day simple moving average of $5.14. The firm has a market capitalization of $361.45 million, a P/E ratio of -6.34 and a beta of 0.07.



A number of institutional investors have recently added to or reduced their stakes in ACIU. Spark Investment Management LLC bought a new stake in AC Immune in the first quarter worth $115,000. Artisan Partners Limited Partnership bought a new position in shares of AC Immune during the first quarter valued at $903,000. Private Advisors LLC bought a new position in shares of AC Immune during the first quarter valued at $202,000. Marshall Wace North America L.P. lifted its holdings in shares of AC Immune by 625.8% during the first quarter. Marshall Wace North America L.P. now owns 15,836 shares of the company’s stock valued at $80,000 after purchasing an additional 13,654 shares in the last quarter. Finally, Appleton Partners Inc. MA bought a new position in shares of AC Immune during the second quarter valued at $85,000. 26.75% of the stock is currently owned by institutional investors and hedge funds.

AC Immune Company Profile (NASDAQ:ACIU)

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

Further Reading: What is the return on assets (ROA) ratio?

Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.